臨床試驗管理系統(CTMS)的全球市場預測(2022年~2027年)
市場調查報告書
商品編碼
1071430

臨床試驗管理系統(CTMS)的全球市場預測(2022年~2027年)

Global Clinical Trial Management System (CTMS) Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球臨床試驗管理系統(CTMS)的市場規模在2020年估算為12億839萬1,000美元,在預測期間內預計將以12.51%的年複合成長率增長,2027年達到27億5,769萬1,000美元。

本報告提供全球臨床試驗管理系統(CTMS)市場調查,提供市場概要,市場規模和預測,趨勢,成長要素及阻礙因素,類型·提供(播送)方式·零組件·終端用戶·用途·各地區的分析,及競爭情形等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提條件

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析
    • 終端用戶談判力
    • 買方議價能力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 產業的競爭情形
  • 產業的價值鏈分析

第5章 全球臨床試驗管理系統(CTMS)市場分析:各類型

  • 簡介
  • 企業CTMS
  • 網站CTMS

第6章 全球臨床試驗管理系統(CTMS)市場分析:提供(播送)模式別

  • 簡介
  • 內部部署
  • 雲端基礎

第7章 全球臨床試驗管理系統(CTMS)市場分析:各零件

  • 簡介
  • 軟體
  • 服務

第8章 全球臨床試驗管理系統(CTMS)市場分析:各終端用戶

  • 簡介
  • 製藥·生物科技企業
  • 委託研究機關
  • 醫療設備廠商
  • 其他

第9章 全球臨床試驗管理系統(CTMS)市場分析:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他

第10章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業和市場收益性
  • 合併,收購,協定,及合作
  • 供應商競爭力矩陣

第11章 企業簡介

  • ArisGlobal LLC
  • RealTime Software Solutions LLC
  • Breeze CTMS
  • Veeva Systems
  • Oracle Corporation
  • Business Systems Integration AG
  • Ennov
  • Bioclinica
  • IBM Corporation
  • Bio-Optronics Inc.
簡介目錄
Product Code: KSI061612086

The global clinical trial management system (CTMS) market was valued at US$1,208.391 million in 2020 and is expected to grow at a CAGR of 12.51% over the forecast period to reach a total market size of US$2,757.691 million by 2027.

The Clinical Trial Management System (CTMS) is a software system used by biotechnology and pharmaceutical industries to handle clinical trials in clinical research. The system keeps track of and handles planning, performance, and reporting tasks, as well as participant contact information and deadlines and milestones. ClinicalTrials currently lists 391,704 studies with sites in all 50 states and 219 countries.

The increased prevalence of chronic and lifestyle-related disorders, as well as a surge in clinical trial outsourcing and implementation by contract research companies, are driving market expansion. According to the Food and Agriculture Organization (FAO), chronic diseases will account for nearly three-quarters of all deaths worldwide by 2020, with developing countries accounting for 71% of deaths due to ischaemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes. Diabetics will increase more than 2.5 times in the developing world, from 84 million in 1995 to 228 million in 2025. Globally, developing nations will bear 60% of the burden of chronic disorders. Furthermore, according to the World Health Organization 2020, major chronic illnesses such as heart disease, stroke, cancer, diabetes, and chronic lung disease account for about 70% of all fatalities globally. Almost three-quarters of all non-communicable disease (NCD) deaths occur in low- and middle-income countries, as do 82% of the 16 million individuals who died prematurely, or before reaching the age of 70.

Furthermore, increasing innovative technology developments to reduce the rising cost of clinical trials have resulted in the development of the clinical trial management system. Although these systems have not been fully adopted owing to a variety of reasons, increasing awareness and the desire to reduce additional expenses associated with clinical trials are likely to boost the market in the future. However, data security concerns and the high cost of clinical trial administration systems are expected to limit market development.

The overall clinical trial management systems market is projected to be dominated by North America. Factors such as increased R&D spending and an increase in demand for medication development are assisting in the expansion of the country's industry under study. According to WHO, 147,213 trials took place in the United States in 2020, which was the highest for any country, followed by 23,051 trials in China and 13,481 in Japan. The growing number of studies and clinical trials, along with increased financing for clinical research, is expected to fuel market growth.

Growth Factors

  • A Growing Number of Clinical Trials:

The increasing number of clinical trials, combined with the availability of sophisticated CTMS systems, is expected to drive market growth. According to WHO, there have been 61,311 trials worldwide in 2020, with a cumulative total of 600,173 trials since 1999. Thus, the increasing number of clinical research studies will boost the use of clinical trial management system solutions, therefore increasing market value. Furthermore, the demand for effective data management and clinical trial result analysis are a few other aspects that are expected to add to market revenue. The deployment and expense of a clinical trial management system, on the other hand, may hinder the market's development.

Restraints:

Budget constraints and high cost Due to limited private financing, stringent regulations, and a bleak financial future, small and mid-sized client facilities frequently encounter budgetary restrictions for clinical trials. Ineffective site selection, poor research design and trial execution, safety concerns, and dropouts due to practical or budgetary constraints are additional instances. Furthermore, the amount of time and money necessary to finish a study grows with each phase. The overall cost of a Phase III failure includes the costs of all previous stages as well as the time that might have been spent testing an alternative medication. According to WHO, as of 2020, 62,603 trials are in Phase III development. Small pharma companies (those with less than $500 million in annual revenue) now account for more than 70% of the roughly 3,000 medicines in phase III clinical trials. Only approximately 20% of medicines now in phase III clinical trials have been launched by large pharma companies (those with annual revenues of $1 billion or more). Each failed study adds to the ever-increasing costs of biopharma R&D. The Congressional Budget Office estimates that in 2019, the pharmaceutical sector spent $83 billion on research and development. The projected cost of developing new medication, including capital expenses and spending on drugs that do not reach the market, ranges from less than $1 billion to more than $2 billion.

COVID-19's Impact on the Clinical Trial Management System (CTMS) Market:

In the midst of the COVID-19 pandemic, the healthcare systems of countries are quickly investing in research and development to battle the virus. Potential chemicals were selected from the CHEMBL and ZINC databases, as well as FDA-approved medicines and molecules in clinical studies. As a result, COVID-19 is projected to have a favourable influence on market growth throughout the forecast period. Cytel Inc. deployed an open-access global COVID-19 Clinical Trial Tracker in April 2020, facilitating massive cooperation among academics, policymakers, doctors, journalists, philanthropists, and other important stakeholders. Similarly, asthe battle to discover an easy-to-administer therapy for the potentially deadly infection heats up, Pfizer Inc and Merck & Co Inc launched additional studies of their investigational oral antiviral medicines for COVID-19 in September 2021.

Key Developments

  • September 2021: PHARMASEAL International Ltd. and Medrio, Inc. collaborated to integrate Medrio's eClinical data collectionsuite with PHARMASEAL's trial management platform, Englity®.
  • August 2021: Verily, an Alphabet subsidiary, has agreed to acquire SignalPath, a clinical trial management system (CTMS) based in Raleigh, North Carolina, that improves the accessibility, quality, and efficiency of clinical research at study sites.

Market Segmentation

  • By Type

Enterprise CTMS

Site CTMS

  • By Delivery Mode

On-premise

Cloud-based

  • By Component

Software

Services

  • By End-User

Pharmaceutical and Biotechnology Companies

Contract Research Organizations

Medical Device Manufacturers

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • UAE
  • South Africa
  • Others

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Clinical Trial Management System (CTMS) Market Analysis, by Type

  • 5.1. Introduction
  • 5.2. Enterprise CTMS
  • 5.3. Site CTMS

6. Global Clinical Trial Management System (CTMS) Market Analysis, by Delivery Mode

  • 6.1. Introduction
  • 6.2. On-premise
  • 6.3. Cloud-based

7. Global Clinical Trial Management System (CTMS) Market Analysis, by Component

  • 7.1. Introduction
  • 7.2. Software
  • 7.3. Services

8. Global Clinical Trial Management System (CTMS) Market Analysis, by End-User

  • 8.1. Introduction
  • 8.2. Pharmaceutical and Biotechnology Companies
  • 8.3. Contract Research Organizations
  • 8.4. Medical Device Manufacturers
  • 8.5. Others

9. Global Clinical Trial Management System (CTMS) Market Analysis, by Geography

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. UK
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. South Africa
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Taiwan
    • 9.6.6. Thailand
    • 9.6.7. Indonesia
    • 9.6.8. Others

10. Competitive Environment and Analysis

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Emerging Players and Market Lucrativenessness
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. Company Profiles 

  • 11.1. ArisGlobal LLC
  • 11.2. RealTime Software Solutions LLC
  • 11.3. Breeze CTMS
  • 11.4. Veeva Systems
  • 11.5. Oracle Corporation
  • 11.6. Business Systems Integration AG
  • 11.7. Ennov
  • 11.8. Bioclinica
  • 11.9. IBM Corporation
  • 11.10. Bio-Optronics Inc.